Key Findings from Recent Multicenter Trials in Pediatric VTE Treatment and Prevention

Venous thromboembolism (VTE) is increasingly being diagnosed in pediatric patients. While an increase may in part be explained by improved identification, VTE has become one of the most common complications of hospitalization in children. Furthermore, the consequences of VTE in childhood can be felt lifelong. Therefore, improving knowledge on pediatric VTE treatment and prevention is a public health priority that should engage patients, parents, pediatric and adult primary care providers, and subspecialists. In this webinar, Drs. Goldenberg and Sochet will discuss key aspects of VTE in children, including incidence, risk factors, and outcomes, as well as critical knowledge gaps in optimal treatment and prevention. They will then summarize the design and findings of two recently published investigator-initiated clinical trials of VTE treatment (Kids-DOTT phase 3 multinational trial on duration of anticoagulation in patients younger than 21 years old with provoked VTE) and prevention (COVAC-TP, U.S. national phase 2 on pharmacological thromboprophylaxis in children hospitalized for COVID-19-related illness, including multisystem inflammatory syndrome in children). Lastly, they will outline key questions for future research. Learning Objectives: 1. Describe the incidence, risk factors, and outcomes of VTE in children. 2. Identify historical knowledge gaps in pediatric VTE treatment and prevention. 3. Describe the latest evidence on the optimal duration of anticoagulation for the treatment of provoked VTE in patients younger than 21 years of age. 4. Describe the safety of enoxaparin thromboprophylaxis in children hospitalized for COVID-19.